Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab

被引：0

作者：

Damassi, Alessandra ^{[1
]}

Cremante, Malvina ^{[1
]}

Signori, Alessio ^{[2
]}

Rebuzzi, Sara Elena ^{[3
,4
]}

Malgeri, Andrea ^{[5
]}

Napoli, Marilena Di ^{[6
]}

Caffo, Orazio ^{[7
]}

Vignani, Francesca ^{[8
]}

Cavo, Alessia ^{[9
]}

Roviello, Giandomenico ^{[10
]}

Prati, Veronica ^{[11
]}

Tudini, Marianna ^{[12
]}

Atzori, Francesco ^{[13
]}

Messina, Marco ^{[14
]}

Morelli, Franco ^{[15
]}

Prati, Giuseppe ^{[16
]}

Nole, Franco ^{[17
]}

Catalano, Fabio ^{[1
]}

Murianni, Veronica ^{[1
]}

Rescigno, Pasquale ^{[18
,19
]}

Banna, Giuseppe Luigi ^{[20
,21
]}

Fornarini, Giuseppe ^{[1
]}

Buti, Sebastiano ^{[22
,23
]}

机构：

[1] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, I-16132 Genoa, Italy

[2] Univ Genoa, Sect Biostat, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy

[3] Osped San Paolo, Med Oncol Unit, I-17100 Savona, Italy

[4] Univ Genoa, Dept Internal Md & Med Specialties DiMI, I-16132 Genoa, Italy

[5] Univ Campus Biomed Roma, Dept Med Oncol, I-00128 Rome, Italy

[6] Ist Ricovero & Cura Carattere Sci IRCCS Fdn G Pasc, Ist Ricovero & Cura Carattere Sci, Dept Urol & Gynecol, Ist Nazl Tumori, I-80131 Naples, Italy

[7] Osped Santa Chiara APSS, Dept Med Oncol, I-38100 Trento, Italy

[8] Ordine Mauriziano Hosp, Div Med Oncol, I-10128 Turin, Italy

[9] Villa Scassi Hosp, Oncol Unit, I-10128 Genoa, Italy

[10] Univ Firenze, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, I-50139 Florence, Italy

[11] Osped Michele & Pietro Ferrero, Dept Gynecol Oncol, Azienda Sanit Locale CN2, I-12060 Verduno, Italy

[12] St Salvatore Hosp, Med Oncol, I-67100 Laquila, Italy

[13] Osped Sirai Carbonia, SSD Oncol Med, ASLSulcis, I-09013 Sirai, Italy

[14] Osped Civ ARNAS, Med Oncol, I-90127 Palermo, Italy

[15] IRCCS Casa Sollievo Sofferenza, Oncol Dept, Foggia, Italy

[16] IRCCS AUSL Reggio Emilia, Dept Oncol & Advances Technol, Reggio Emilia, Italy

[17] European Inst Oncol IRCCS, Med Oncol Div Urogenital Head Neck Tumors, IEO, I-20141 Milan, Italy

[18] Newcastle Univ, Translat & Clin Res Inst, Ctr Canc, Newcastle Upon Tyne NE7 7DN, England

[19] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, Italy

[20] Portsmouth Hosp Univ NHS Trust, Portsmouth PO6 3LY, England

[21] Univ Portsmouth, Fac Sci & Hlth, Sch Pharm & Biomed Sci, Portsmouth PO12UP, England

[22] Univ Hosp Parma, Med Oncol Unit, I-43126 Parma, Italy

[23] Univ Parma, Dept Med & Surg, I-43121 Parma, Italy

来源：

IMMUNOTHERAPY | 2024年 / 16卷 / 18-19期

关键词：

IMDC score; meet-URO score; metastatic renal cell carcinoma; nivolumab; treatment sequence; tyrosine kinase inhibitor; SUNITINIB;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received >= second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.

引用

页码：1095 / 1103

页数：9

共 50 条

[1] Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
Damassi, Alessandra
Cremante, Malvina
Signori, Alessio
Rebuzzi, Sara Elena
Malgeri, Andrea
Napoli, Marilena Di
Caffo, Orazio
Vignani, Francesca
Cavo, Alessia
Roviello, Giandomenico
Prati, Veronica
Tudini, Marianna
Atzori, Francesco
Messina, Marco
Morelli, Franco
Prati, Giuseppe
Nole, Franco
Catalano, Fabio
Murianni, Veronica
Rescigno, Pasquale
Banna, Giuseppe Luigi
Fornarini, Giuseppe
Buti, Sebastiano
IMMUNOTHERAPY, 2024,
[2] Prognostic biomarker exploration for patients with metastatic renal cell carcinoma receiving VEGFR TKI.
Park, Lnkeun
Cho, Yong Mee
Lee, Jae-Lyun
Ahn, Jin-Hee
Lee, Dan Ho
You, Dalsan
Jeong, In Gab
Song, Cheryn
Hong, Burn-Sik
Hong, Jun Hyuck
Ahn, Hanjong
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[3] Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
Yamashita, Shimpei
Hamamoto, Shuzo
Furukawa, Junya
Fujita, Kazutoshi
Takahashi, Masayuki
Miyake, Makito
Ito, Noriyuki
Iwamoto, Hideto
Kohjimoto, Yasuo
Hara, Isao
SCIENTIFIC REPORTS, 2024, 14 (01):
[4] Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
Catalano, Martina
Rebuzzi, Sara Elena
Maruzzo, Marco
De Giorgi, Ugo
Buti, Sebastiano
Galli, Luca
Fornarini, Giuseppe
Zucali, Paolo Andrea
Procopio, Giuseppe
Chiellino, Silvia
Milella, Michele
Catalano, Fabio
Pipitone, Stefania
Ricotta, Riccardo
Soraru, Mariella
Mollica, Veronica
Tudini, Marianna
Fratino, Lucia
Prati, Veronica
Caffo, Orazio
Atzori, Francesco
Morelli, Franco
Prati, Giuseppe
Nole, Franco
Vignani, Francesca
Cavo, Alessia
Di Napoli, Marilena
Malgeri, Andrea
Naglieri, Emanuele
Signori, Alessio
Banna, Giuseppe Luigi
Rescigno, Pasquale
Antonuzzo, Lorenzo
Roviello, Giandomenico
JAMA NETWORK OPEN, 2023, 6 (11) : E2345185
[5] Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma
Yudai Ishiyama
Tsunenori Kondo
Hidekazu Tachibana
Hiroki Ishihara
Hironori Fukuda
Kazuhiko Yoshida
Toshio Takagi
Junpei Iizuka
Kazunari Tanabe
International Journal of Clinical Oncology, 2021, 26 : 552 - 561
[6] Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma
Ishiyama, Yudai
Kondo, Tsunenori
Tachibana, Hidekazu
Ishihara, Hiroki
Fukuda, Hironori
Yoshida, Kazuhiko
Takagi, Toshio
Iizuka, Junpei
Tanabe, Kazunari
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) : 552 - 561
[7] Prognostic value of lymphnode metastases in patients with metastatic renal cell carcinoma
Eggers, H.
Tiemann, M. -L
Peters, I
Kuczyk, M. A.
Ganser, A.
Gruenwald, V
Ivanyi, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 275 - 275
[8] Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab
Tomcova, Zuzana
Obertova, Jana
Chovanec, Michal
Sycova-Mila, Zuzana
Stefanikova, Katarina
Slachtova, Eva
Zak, Monika
Savka, Alexander
Hrncar, Matej
Rejlekova, Katarina
Palacka, Patrik
BIOMEDICINES, 2025, 13 (02)
[9] Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma
Yamamoto, Yoshiaki
Matsuyama, Hideyasu
Matsumoto, Hiroaki
Sakano, Shigeru
Fuji, Nakanori
Oba, Kazuo
Yamamoto, Mitsutaka
Kamiryo, Yoriaki
Hiragino, Takeshi
Nagao, Kazuhiro
Takai, Kimio
Aoki, Akihiko
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (02) : 214 - 220
[10] Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
Wakita, Naoto
Hinata, Nobuyuki
Bando, Yukari
Hara, Takuto
Terakawa, Tomoaki
Furukawa, Junya
Nakano, Yuzo
Fujisawa, Masato
ANTICANCER RESEARCH, 2023, 43 (02) : 841 - 847

← 1 2 3 4 5 →